Overview

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.

Phase:

Phase 3

Details

Lead Sponsor:

Médecins Sans Frontières, France

Collaborators:

Epicentre
Harvard Medical School
Harvard Medical School (HMS and HSDM)
Institute of Tropical Medicine, Belgium
Interactive Research and Development
Partners in Health
Socios En Salud, Peru
University of San Francisco

Treatments:

Bedaquiline
Clofazimine
Diarylquinolines
Fluoroquinolones
Linezolid